ABVX

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research PARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that seven scientific abstracts on obefazimod, its lead drug candidate for

F-6EF - Abivax S.A. (0001956827) (Subject)

6-K - Abivax S.A. (0001956827) (Filer)

Abivax Presents Business Updates and First Half 2026 Financial Results  Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and Controls ("CMC"), Quality and Information Technology ("IT") functionsCash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritten public offering, provides cash runway into Q4 2029Royalty certificates buy-back completed in Q2 2026 materially reduces royalty overhang, further strengthening Abivax’s debt-free financial position

SCHEDULE 13G/A - Abivax S.A. (0001956827) (Subject)

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026 PARIS, France – July 30, 2026 – 10:05 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the successful completion of its positive pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Adm

Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Appointed industry leaders bring decades of experience across commercial strategy, patient services, launch readiness, and field force development PARIS, France – July 23, 2026 – 10:05 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the expansion of its Commercial Leadership Team with four strategic appointments spanning marketing, patient services, sales, comme

SCHEDULE 13D/A - Abivax S.A. (0001956827) (Subject)

Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 7,360,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States (the "Offering"), which includes the full exercise of t

6-K - Abivax S.A. (0001956827) (Filer)

424B5 - Abivax S.A. (0001956827) (Filer)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) PARIS, France, July 2, 2026 – 8:00 a.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces that the underwriters of its offering of 6,400,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States (the "

FWP - Abivax S.A. (0001956827) (Subject)

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a 2.39% premium to the three-day VWAPExpected gross proceeds of approximately $800M (€702M), before potential exercise of the Underwriters’ Option, are anticipated to extend the Company's cash runway into Q2 2029, supporting potential commercialization of obefazimod and continued clinical development PARIS, France, July 1, 2026 – 2:30 p.m. (CEST) – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST. Trading of the ordinary shares of the Company was halted at the request of the Company on July 1, 2026 from 9:00 a.m. CEST in the context of the previously announced public offering by the Com

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a 2.39% premium to the three-day VWAPExpected gross proceeds of approximately $800M (€702M), before potential exercise of the Underwriters’ Option, are anticipated to extend the Company's cash runway into Q2 2029, supporting potential commercialization of obefazimod and continued clinical development PARIS, France, July 1, 2026 – 2:30 p.m. (CEST) – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therap

Jefferies upgraded Abivax SA from Hold to Buy and set a new price target of $158.00

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced public offering by th

FWP - Abivax S.A. (0001956827) (Subject)

424B5 - Abivax S.A. (0001956827) (Filer)

Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the launch of an underwritten public offering of approximately $600 million (approximately €527 million) of its American Depositary Shares ("ADSs"), each representing one ordinary share of Abivax, nominal value €0.01 per share (each, an "Ordinary Share"), in the United States (the "Offer

POSASR - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database Obefazimod delivered meaningful clinical benefit in a highly refractory ulcerative colitis ("UC") population, with 37.2% of induction non-responders achieving clinical remission and 34.5% achieving endoscopic remission at Week 44 following continued 50 mg treatmentDose escalation to obefazimod 50 mg recaptured clinical remission in 45.5% of patients who relapsed during ABTECT Maintenance Part 1, supporting a practical dose-escalation strategy for regaining and sustaining disease

Jefferies downgraded Abivax SA from Buy to Hold and set a new price target of $90.00